RA Capital Management ASMB Position
ActiveRA Capital Management held their position in ASSEMBLY BIOSCIENCES, INC. (ASMB) in Q4 2025, holding $34.7M worth of shares across 1,020,410 shares.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
1 other tracked fund also holds ASMB.
Short interest stands at 11.2% of float with 14.2 days to cover, indicating significant bearish positioning against RA Capital's long thesis.
About ASSEMBLY BIOSCIENCES, INC.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
11.2%
14.2 days to cover
RA Capital Management ASMB Position History
Frequently Asked Questions
Does RA Capital Management own ASMB?
Yes. As of Q4 2025, RA Capital Management holds 1,020,410 shares of ASSEMBLY BIOSCIENCES, INC. (ASMB) valued at $34.7M. This data comes from their SEC 13F filing.
How many hedge funds own ASMB?
2 specialist biotech hedge funds currently hold ASMB, including Commodore Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did RA Capital Management first buy ASMB?
RA Capital Management's position in ASMB was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is RA Capital Management's ASMB position increasing or decreasing?
RA Capital Management held their ASMB position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ASMBCompany Page →
All fund holders, insider trades, catalysts, and cash runway
RA Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →